Journal Scans
Zalutumumab Plus Best Supportive Care Versus Best Supportive Care Alone in Patients With Recurrent or Metastatic Squamous-Cell Carcinoma of the Head and Neck After Failure of Platinum-Based Chemotherapy: an Open-Label, Randomised Phase 3 Trial
Zalutumumab Plus Best Supportive Care Beneficial In SCCHN
J-P Machiels, S Subramanian, A Ruzsa, G Repassy, I Lifirenko, A Flygare, P Sørensen, T Nielsen, S Lisby, PMJ Clement
Yes
20110207
2011 Mar 7
Lancet Oncol
Zalutumumab Plus Best Supportive Care Versus Best Supportive Care Alone in Patients With Recurrent or Metastatic Squamous-Cell Carcinoma of the Head and Neck After Failure of Platinum-Based Chemotherapy: an Open-Label, Randomised Phase 3 Trial
Lancet Oncol. 2011 Mar 7;[Epub Ahead of Print], J-P Machiels, S Subramanian, A Ruzsa, G Repassy, I Lifirenko, A Flygare, P Sørensen, T Nielsen, S Lisby, PMJ Clement
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
Abstract
Background: No treatments are presently available to increase survival in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy. We aimed to assess efficacy and safety of zalutumumab, a human IgG1 monoclonal antibody targeting the epidermal growth factor receptor, for overall survival in such patients. Methods: In our open-label, parallel-group, phase 3, randomised trial, we randomly allocated patients with squamous-cell carcinoma...
